3 Pathology and Radiology Chain, High-Volume Testing Lab and Single-Use Medical Devices Stocks With a Strong Future Roadmap: Vijaya Diagnostic Centre, Thyrocare Technologies and Poly Medicure
- October 23, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Vijaya Diagnostic Centre, Thyrocare Technologies and Poly Medicure: ROE of 10.4% to 27.9% and FY22 to FY26 revenue CAGR of 8.2% to 20.0%. Prices as of 22 Oct 2026.
Quick Answer
The three diagnostic chain and medical consumables stocks to watch are Vijaya Diagnostic Centre, Thyrocare Technologies and Poly Medicure. Their return on equity ranges from 10.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 20.0%. Thyrocare Technologies has the highest return on equity at 27.9%, while Poly Medicure has the fastest revenue growth at 20.0% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Diagnostic chain and medical consumables stocks let investors follow companies that test patients and supply the disposables used in care. Vijaya Diagnostic Centre, Thyrocare Technologies and Poly Medicure cover a pathology and radiology chain, a high-volume testing laboratory and a maker of single-use medical devices.
This list covers three diagnostic chain and medical consumables stocks with complete current figures: Vijaya Diagnostic Centre, Thyrocare Technologies and Poly Medicure. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Diagnostic Chain and Medical Consumables Stocks?
Diagnostic chain and medical consumables stocks are listed companies that run test centres or make disposable devices such as infusion sets and syringes. Their earnings depend on test volumes, hospital demand and export orders.
Diagnostic Chain and Medical Consumables Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Vijaya Diagnostic Centre | 1,390.8 | 14,066 | 75.0 | 59.6 | 18.1 | 0.44 |
| Thyrocare Technologies | 472.1 | 7,501 | 42.6 | 59.6 | 27.9 | 0.09 |
| Poly Medicure | 1,448.9 | 15,721 | 50.2 | 59.6 | 10.4 | 0.11 |
On valuation, Thyrocare Technologies and Poly Medicure trade at a P/E below the industry P/E, while Vijaya Diagnostic Centre trades above it, which reflects the growth the market already expects. Readers comparing diagnostic chain and medical consumables stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in diagnostic chain and medical consumables stocks can use the coming numbers to test whether growth is holding.
Why Do Diagnostic Chain and Medical Consumables Stocks Have a Strong Roadmap in India?
Diagnostic chain and medical consumables stocks have a strong roadmap in India because wider access to testing and steady growth in procedures keep adding demand for both lab services and disposables.
- Preventive testing. More people opt for regular check-ups and screening.
- Collection reach. Partner networks bring tests to smaller towns.
- Export demand. Disposable devices find buyers in many countries.
Why Vijaya Diagnostic Centre Features Among These Diagnostic Chain and Medical Consumables Stocks
Among the diagnostic chain and medical consumables stocks on this list, Vijaya Diagnostic Centre is a Hyderabad-headquartered diagnostics chain that offers pathology and radiology services through a network of centres, with Hyderabad and Telangana as its home base.
In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%.
Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6.
Roadmap: The plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.
What to watch: Check the revenue contribution from newer regions and the pace at which new centres turn profitable.
Why Thyrocare Technologies Features Among These Diagnostic Chain and Medical Consumables Stocks
Among the imaging and lab testing shares on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.
The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6.
Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore.
Roadmap: The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.
What to watch: Track growth in test volume per day and the share of revenue from preventive health packages.
Why Poly Medicure Features Among These Diagnostic Chain and Medical Consumables Stocks
Among the three companies on this list, Poly Medicure makes single-use medical devices such as infusion sets, syringes, catheters, blood management products and dialysis consumables, and it exports to many countries.
Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%.
In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6.
Roadmap: The company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.
What to watch: Track export growth, new product approvals and plant capacity use.
Vijaya Diagnostic Centre vs Thyrocare Technologies vs Poly Medicure on Key Financials
The table below sets the three diagnostic chain and medical consumables stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Vijaya Diagnostic Centre | 475 | 835 | 15.1% | 173 | 20.7% |
| Thyrocare Technologies | 618 | 846 | 8.2% | 163 | 19.2% |
| Poly Medicure | 961 | 1,995 | 20.0% | 321 | 16.1% |
Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Poly Medicure combines the largest FY26 revenue at Rs 1,995 crore with the fastest revenue growth, a 20.0% compound annual rate. A useful habit with diagnostic chain and medical consumables stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several single-use medical device stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Vijaya Diagnostic Centre | 195 | 240 | 22.8% |
| Thyrocare Technologies | 198 | 244 | 23.5% |
| Poly Medicure | 445 | 559 | 25.5% |
Key Risks to Check Before Investing in Diagnostic Chain and Medical Consumables Stocks
Every theme carries risks that deserve a check before any decision. For these diagnostic chain and medical consumables stocks, the main points are: Long-term imaging and lab testing shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Competition and procurement rules can limit pricing.
- Capacity timing. New centres and plants take time to ramp up.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter diagnostic chain and medical consumables stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Diagnostic Chain and Medical Consumables Stocks
Diagnostic chain and medical consumables stocks reward investors who follow test volumes, capacity and exports together. Vijaya Diagnostic Centre, Thyrocare Technologies and Poly Medicure each serve a different step in care. Based on the 22 October 2026 close, Vijaya Diagnostic Centre trades at Rs 1,390.8, Thyrocare Technologies at Rs 472.1 and Poly Medicure at Rs 1,448.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these diagnostic chain and medical consumables stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track diagnostic chain and medical consumables stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are diagnostic chain and medical consumables stocks?
Ans. Diagnostic chain and medical consumables stocks are listed companies that run test centres or make disposable devices such as infusion sets and syringes. Their earnings depend on test volumes, hospital demand and export orders. This list looks at three of them, Vijaya Diagnostic Centre, Thyrocare Technologies and Poly Medicure, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which diagnostic chain and medical consumables stocks are covered in this list?
Ans. This list covers Vijaya Diagnostic Centre, Thyrocare Technologies and Poly Medicure. Based on the 22 October 2026 close, Vijaya Diagnostic Centre traded at Rs 1,390.8, Thyrocare Technologies at Rs 472.1 and Poly Medicure at Rs 1,448.9. Their return on equity ranges from 10.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 20.0%.
Why do diagnostic chain and medical consumables stocks have a strong future roadmap in India?
Ans. Diagnostic chain and medical consumables stocks have a strong roadmap in India because wider access to testing and steady growth in procedures keep adding demand for both lab services and disposables. The main drivers are as follows. Preventive testing. More people opt for regular check-ups and screening. Collection reach. Partner networks bring tests to smaller towns. Export demand. Disposable devices find buyers in many countries. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Vijaya Diagnostic Centre performed financially?
Ans. Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6. Looking ahead, the plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.
How has Thyrocare Technologies performed financially?
Ans. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.
How has Poly Medicure performed financially?
Ans. Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6. Looking ahead, the company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.
What risks should investors check before buying diagnostic chain and medical consumables stocks?
Ans. Investors should check a few risks before buying diagnostic chain and medical consumables stocks. Pricing pressure. Competition and procurement rules can limit pricing. Capacity timing. New centres and plants take time to ramp up. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of diagnostic chain and medical consumables stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
